If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Decarbonization Plus Acquistion (DCRBU)
Helix Acquisition (HLXA)
Upcoming IPO
Mallard Acquisition (MACUU)
MingZhu Logistics Holdings (YGMZ)
Good Works Acquisition (GWACU)
Bull Horn Holdings (BHSEU)
Horizon Acquisition II (HZON.U)
Datto Holding Corp. (MSP)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Foghorn Therapeutics Inc. (FHTX)
Gatos Silver, Inc. (GATO)
Priced IPO
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
fuboTV Inc. (FUBO)
Presidio Property Trust (SQFT)
Academy Sports and Outdoors, Inc. (ASO)
Immunome Inc. (IMNM)
C4 Therapeutics, Inc. (CCCC)
Oncorus, Inc (ONCR)
More companies

C4 Therapeutics, Inc. (CCCC)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biopharmaceutical company focused on transforming the treatment of cancer, serious neurodegenerative conditions and other diseases by developing novel therapeutic candidates engineered to harness the body’s natural regulation of protein levels to target and destroy disease-causing proteins. They leverage their proprietary technology platform, TORPEDO (Target ORiented ProtEin Degrader Optimizer), to synthesize a new class of small molecule protein degraders that selectively and efficiently destroy disease-causing proteins. They are using their TORPEDO platform to build a robust pipeline of orally administered protein degradation drug candidates, with an initial focus on oncology indications. Their approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients. One of their lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, or MM, peripheral T-cell lymphoma, or PTCL, and mantle cell lymphoma, or MCL. They expect to submit an investigational new drug application, or IND, for this product candidate to the FDA in the fourth quarter of 2020 and begin a first-in-human Phase 1/2 clinical trial for this product in the first half of 2021.
Employees Founded
88 2015


Address: 490 Arsenal Way, Suite 200 Watertown, MA 02472

Telephone: 617) 231-0700

Web page:

IPO information

Expected Date 10/2/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $693.09
Revenues (MM) $0
Net Income (Loss) (MM) $-34.1


What do you think will happen with the CCCC share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.8
Shares Revised (MM) 9.6
Expected offer amount (MM) $149.6
Realized offer amount(MM) $182.4
Jefferies/ Evercore ISI/ BMO Capital Markets/ UBS Investment Bank

Sector: Healthcare

Tweets about $CCCC

Tweets volume:

RT volume:


Google Trends Stats